Results of a Survey of Patients with Alpha-1 Antitrypsin DeficiencyStrange C.a · Stoller J.K.b · Sandhaus R.A.c · Dickson R.a · Turino G.d
aDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Medical University of South Carolina, Charleston, S.C.; bDivision of Pulmonary, Allergy, and Critical Care Medicine, Cleveland Clinic Foundation, Cleveland, Ohio; cDivision of Pulmonary and Critical Care Medicine, National Jewish Medical Center, Denver, Colo., and dDivision of Pulmonary Medicine, St. Luke’s/Roosevelt Hospital, New York, N.Y., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: α1-Antitrypsin deficiency (AATD) is an uncommon genetic disease which occurs in 1–2.5% of Americans with chronic obstructive pulmonary disease (COPD). Little is known about current demographics of AATD. Objectives: This survey study reviews the clinical characteristics of diseased individuals in North America. Methods: A survey of members from the mailing lists of US AATD patient support organizations was commissioned with duplicate persons omitted. The survey was mailed to 5,222 unique individuals with AATD. Questionnaires were returned by 1,953 individuals, including 1,810 with severe deficiency, 93 with the carrier state and 41 who were caregivers of others. Results: The majority (81%) of participants reported COPD with symptoms of asthma, chronic bronchitis, and emphysema, usually in combination. The mean age of respondents [53.1 ± 13.2 (SD) years] is older than the general US population. Lung or liver transplantation was reported by 9% of all respondents (n = 175), including 66 single lung transplants, 68 double lung transplants, and 47 liver transplants. Another 6.6% (n = 128) reported that they were currently on a transplant list. Twenty-one percent of lung transplants report continuing augmentation therapy use. Augmentation use is reported by 75% of those with obstructive lung disease. The majority of patients with liver disease also have COPD. Conclusions: AATD remains a devastating illness for many of those affected as reflected in a high incidence of transplantation for liver and lung disease.
© 2006 S. Karger AG, Basel
American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med 2003;168:818–900.
- de Serres FJ: Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002;122:1818–1829.
- Sveger T: Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976;294:1316–1321.
- Stoller J, Smith P, Yang P, et al: Physical and social impact of alpha1 antitrypsin deficiency: results of a study. Cleveland Clin J Med 1994;61:461–467.
- McElvaney NG, Stoller JK, Buist AS, et al: Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1997;111:394–403.
- Silverman E, Province M, Campbell E, et al: Family study of alpha1-antitrypsin deficiency: Effects of cigarette smoking, measured genotype, and their interaction on pulmonary function and biochemical traits. Genet Epidemiol 1992;9:317–331.
- Mayer AS, Stoller JK, Bucher-Bartelson B, et al: Occupational exposure risks in individuals with PI*Z alpha(1)-antitrypsin deficiency. Am J Respir Crit Care Med 2000;162:553–558.
- Black LF, Kueppers F: Alpha 1-antitrypsin deficiency in nonsmokers. Am Rev Respir Dis 1978;117:421–428.
Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998;158:49–59.
- Stoller JK, Fallat R, Schluchter MD, et al: Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest 2003;123:1425–1434.
- Zorzetto M, Tamburnotti C, Maschietto B, et al: A fast amplification-reverse hybridization assay kit to detect the most frequesnt deficient variants in the alpha-1-antitrypsin gene. Respiration 2002;69:81–85.
- Turino GM, Barker AF, Brantly ML, et al: Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. Alpha 1-antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1996;154:1718–1725.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.